Kura Oncology’s (KURA) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Friday, Benzinga reports. Wedbush currently has a $37.00 price target on the stock.

Several other research analysts have also weighed in on the stock. JMP Securities increased their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a report on Wednesday, January 31st. StockNews.com lowered shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. Finally, HC Wainwright reiterated a buy rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, April 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $28.28.

Kura Oncology Price Performance

Kura Oncology stock opened at $21.01 on Friday. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The stock has a market capitalization of $1.60 billion, a P/E ratio of -9.68 and a beta of 0.89. The firm’s 50-day moving average is $20.66 and its two-hundred day moving average is $16.13. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.67 and a quick ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period in the prior year, the business earned ($0.50) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts predict that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KURA. Signaturefd LLC raised its holdings in Kura Oncology by 40.4% in the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after buying an additional 1,449 shares during the period. Pale Fire Capital SE purchased a new position in Kura Oncology in the third quarter valued at approximately $92,000. E Fund Management Co. Ltd. raised its holdings in Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after buying an additional 1,301 shares during the period. SG Americas Securities LLC acquired a new stake in Kura Oncology in the first quarter valued at approximately $110,000. Finally, AXQ Capital LP acquired a new stake in Kura Oncology in the third quarter valued at approximately $118,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.